Fig. 5
Intestinal pathologies of tunicamycin-treated wild-type larvae. (A) ISH with fabp2 shows smaller intestine in tunicamycin (TN)-treated larvae. (B) Confocal projections of Tg(fabp2:egfp) intestine (white outline) showing disrupted intestinal architecture of tunicamycin-treated larvae. (C) H&E-stained sections shows abnormal GCs (arrows) and increased luminal bacteria (arrowheads) in tunicamycin-treated larvae. (D) Bar charts showing reduced gut size, GC depletion and increased intestinal bacteria in tunicamycin-treated larvae (n≥10). (E) Confocal projection of Tg(lyzc:egfp) larval intestine shows increased macrophage aggregation (arrows) in tunicamycin-treated larvae (n=15). (F) Confocal projection of Tg(lc3:gfp) intestine shows increased autophagosomes (arrows) in tunicamycin-treated larvae (n=7). *P<0.05, **P<0.01, ***P<0.001. Scale bars: 100 µm (B,E); 20 µm (C); 5 µm (F).